Baltimore, MD, July 17, 2013 – UM Ventures has signed a licensing agreement with Rockville, Md.-based Rexahn Pharmaceuticals, Inc. for a newly-developed cancer drug delivery platform, Nano-Polymer-Drug Conjugate Systems (NPDCS). The technology helps target cancer-fighting drugs directly to tumors, minimizing toxicity levels in the rest of the body.
“This discovery – as well as the partnership with a leading Maryland-based biopharmaceutical company – is very exciting for UMB, and Rexahn is exactly the type of focused organization that our office seeks out as a commercial partner,” said Phil Robilotto, Assistant Vice President, UMB Office of Technology Transfer. “The initial funding for this work was provided through a Maryland Industrial Partnership (MIPS) award, and a successful long term university/industry relationship such as this is a terrific example of the value of the MIPS program.”
To learn more about NPDCS technology and the licensing agreement, read Rexahn’s press release here.
UM Ventures is an initiative to channel the tremendous technical resources and research expertise of the University of Maryland engaging partners in industry and social ventures to expand our real world impact. By encouraging our students and faculty, providing expert advice and business services, more discoveries will reach the market. By engaging directly with external partners we will bring new investment, expanded markets and more start-up ventures.
Read more about UM Ventures here.
For more information, contact Alex Likowski at firstname.lastname@example.org or (410) 706-3801.